Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures

成骨细胞衍生的WNT16抑制破骨细胞生成,预防皮质骨脆性骨折。

阅读:2
作者:Sofia Movérare-Skrtic ,Petra Henning ,Xianwen Liu ,Kenichi Nagano ,Hiroaki Saito ,Anna E Börjesson ,Klara Sjögren ,Sara H Windahl ,Helen Farman ,Bert Kindlund ,Cecilia Engdahl ,Antti Koskela ,Fu-Ping Zhang ,Emma E Eriksson ,Farasat Zaman ,Ann Hammarstedt ,Hanna Isaksson ,Marta Bally ,Ali Kassem ,Catharina Lindholm ,Olof Sandberg ,Per Aspenberg ,Lars Sävendahl ,Jian Q Feng ,Jan Tuckermann ,Juha Tuukkanen ,Matti Poutanen ,Roland Baron ,Ulf H Lerner ,Francesca Gori ,Claes Ohlsson

Abstract

The WNT16 locus is a major determinant of cortical bone thickness and nonvertebral fracture risk in humans. The disability, mortality and costs caused by osteoporosis-induced nonvertebral fractures are enormous. We demonstrate here that Wnt16-deficient mice develop spontaneous fractures as a result of low cortical thickness and high cortical porosity. In contrast, trabecular bone volume is not altered in these mice. Mechanistic studies revealed that WNT16 is osteoblast derived and inhibits human and mouse osteoclastogenesis both directly by acting on osteoclast progenitors and indirectly by increasing expression of osteoprotegerin (Opg) in osteoblasts. The signaling pathway activated by WNT16 in osteoclast progenitors is noncanonical, whereas the pathway activated in osteoblasts is both canonical and noncanonical. Conditional Wnt16 inactivation revealed that osteoblast-lineage cells are the principal source of WNT16, and its targeted deletion in osteoblasts increases fracture susceptibility. Thus, osteoblast-derived WNT16 is a previously unreported key regulator of osteoclastogenesis and fracture susceptibility. These findings open new avenues for the specific prevention or treatment of nonvertebral fractures, a substantial unmet medical need.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。